Novo Nordisk recalls GlucaGen HypoKit in US after error at syringe supplier

By Gareth Macdonald contact

- Last updated on GMT

Novo Nordisk recalls GlucaGen HypoKit in US after error at syringe supplier

Related tags: Insulin

Novo Nordisk has recalled six lots of its GlucaGen HypoKit pen in the US after customers in Europe complained of detached needles.

The Danish firm announced the recall last week, explaining the move followed “two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI).”

The GlucaGen HypoKit pen – which has been available in the US since 2005 - is used to deliver a recombinant version of the peptide hormone glucagon. It is used to treat severe hypoglycemia – low blood sugar – in patients with insulin-dependent diabetes.

Novo spokeswoman Mette Kruse Danielsen told us “the root cause was a manufacturing error at the supplier of the glass syringe that is used together with the vial containing freeze dried glucagon​.”

Danielsen also confirmed the device was made by a third party, but declined to name the company involved.

She added that: “Novo Nordisk has in cooperation with the supplier instituted corrective actions to avoid re-occurrence."

Note: Our email newsletter strap line incorrectly stated that the recalled product is an "insulin pen." 

Related topics: Drug Delivery, Delivery technologies, QA/QC

Related news

Show more

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us

Products

View more

Webinars